Using reminders and self-sampling to boost cervical cancer screening participation
Official title: Research Project on Reminders and Self-Sampling Can Increase Participation in Gynecology Cell Sampling - Preventive Examination Against Cervical Cancer.
Run by Karolinska Institutet · NCT04061967 · Data updated 2026-11-12
This study is testing if sending text reminders and using self-sampling kits can help women at high risk for cervical cancer get screened more often.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 33 Years to 75 Years |
| Sex | Women only |
| Enrollment | 20000 (estimated) |
| Sponsor | Karolinska Institutet Academic / other |
| Locations | 6 sites (Luleå, Norrbotten County and 5 other locations) |
| Status | Recruiting |
| Started | August 19, 2019 |
| Main results expected | June 1, 2030 |
| Study ends | June 1, 2030 |
| Registry record updated | January 14, 2025 |
| Trial ID | NCT04061967 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are women residing in Region Skåne who have not participated in cervical screening for an extended period or have had abnormal results that were not followed up.
✕Probably not a fit
Patients who have consistently participated in cervical cancer screening or do not consent to the study will not benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to enhance participation in cervical cancer screening by utilizing SMS reminders and electronic letters instead of traditional physical mail. The study targets women at high risk for cervical cancer who have not adequately participated in screening programs. By offering self-sampling kits for HPV testing, the study seeks to reduce barriers to screening and improve follow-up care for women with abnormal results. Women are identified through registry linkages that assess their screening history and risk status, and those who qualify will receive invitations to participate.
Why it matters
Potential benefit: If successful, this approach could significantly increase cervical cancer screening rates and reduce the incidence of cervical cancer among women.
How similar studies have gone: Previous studies have shown that self-sampling and reminder systems can effectively increase participation in cervical cancer screening, indicating a promising approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women resident in Region Skane who either: 1) have had glandular cell transformation that has not been followed-up, 2) are older than 65 years and have had cell transformation that has not been followed-up or who have not participated in screening during the last 10 years, 3) women who have not been screened for more than 15 years. Exclusion Criteria: * No exclusion except those who do not consent.
Where it's running
-
Northern Region
Luleå, Norrbotten County, Sweden Recruiting -
Southern Region
Lund, Skåne County, Sweden Recruiting -
Western Region
Gothenburg, Västra Götaland County, Sweden Recruiting -
Southeast Region
Jönköping, Sweden Recruiting -
Region of Stockholm-Gotland
Stockholm, Sweden Recruiting -
Region of Middle Sweden
Uppsala, Sweden Recruiting
Study contacts
- Principal investigator: Miriam Elfström, PhD — Karolinska Institutet
- Study coordinator: Miriam Elfström, PhD
- Email: Miriam.elfstrom@sll.se
- Phone: +46(0)703816277
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treatment with STAR0602 for advanced solid tumors
This study is testing a new treatment called STAR0602 to see if it can help people with advanced solid tumors by looking at how safe it is and how well it works.
-
Early intervention strategies for lung cancer detection
This study is testing if using low-dose CT scans in community health centers can help find lung cancer earlier in people aged 40-75 who don't have a history of the disease.
-
Using 18F-Fluciclovine PET/CT to Predict Outcomes of Prostate Cancer Therapy
This study is testing if special imaging can help predict how well a new prostate cancer treatment works for patients with advanced disease.
-
Combination treatment for brain metastasis from ER+/HER-2- breast cancer
This study is testing a new combination treatment of elacestrant and abemaciclib to see if it can help people with brain metastases from estrogen receptor-positive, HER-2 negative breast cancer.
-
Pooling clinical experiences of patients treated with Lutetium-177 in Spain
This study looks at how well Lutetium-177 works and how safe it is for patients with certain types of tumors in Spain by collecting information from their medical records.
-
Registry for patients with unresectable pancreatic cancer treated with OncoSil™
This study is testing how well the OncoSil™ device works and its safety for people with advanced pancreatic cancer who are also receiving chemotherapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.